Yijielike

Yijielike (Shanghai) Biotechnology is a clinical-stage biopharmaceutical company based in China that focuses on the development of innovative small molecule and antibody-based therapies for oncology. The company primarily targets tyrosine kinase pathways, including MET, VEGFR, and AXL, to address unmet needs in solid tumors such as liver and kidney cancers. Yijielike is actively involved in clinical trials within the Chinese market, aiming to provide more effective treatment options for cancer patients. Their business model encompasses the full lifecycle of drug development, from discovery and preclinical research to clinical validation.